Psychotropic medication in adults with mental retardation: Prevalence, and prescription practices

Research in Developmental Disabilities

Volumn 25, Issue 6, 2004, Pages 509-521

  Holden, Børge ^a   Gitlesen, Jens Petter ^b  

^a Hedmark Næringspark Bygg 15 ^*  (Norway)

^b UNIVERSITY OF STAVANGER   (Norway)

Author keywords

Prescription practices; Prevalence; Psychotropic medication

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CENTRAL STIMULANT AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZUCLOPENTHIXOL;

ADULT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; FEMALE; GENERAL PRACTITIONER; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MENTAL DISEASE; NORWAY; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHIATRIST; SIDE EFFECT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DRUG UTILIZATION; FAMILY PRACTICE; FEMALE; GUIDELINE ADHERENCE; HUMANS; LONG-TERM CARE; MALE; MENTAL DISORDERS; MENTAL RETARDATION; MIDDLE AGED; NORWAY; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; PSYCHOTROPIC DRUGS; SOCIAL BEHAVIOR DISORDERS;

EID: 8444222841     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2004.03.004     Document Type: Article

References (21)

1. Ahmed Z., Fraser W., Kerr M.P., Kiernan C., Emerson E., Robertson J., et al. Reducing antipsychotic medication in people with a learning disability. British Journal of Psychiatry. 176:2000;42-46
2. Aman, M. G., & Singh, N. N. (1988). Psychopharmacology of the developmental disabilities. Berlin: Springer-Verlag.
3. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (DSM-IV) (4th ed.). Washington, DC: APA.
4. Baumeister A.A., Sevin J.A. Pharmacologic control of aberrant behavior in the mentally retarded: Toward a more rational approach. Neuroscience and Biobehavioral Reviews. 14:1990;253-262
5. Branford D. Factors associated with the successful of unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities. Journal of Intellectual Disability Research. 40:1996;322-329
6. Campbell J.M. Efficacy of behavioral interventions for reducing problem behavior in persons with autism: A quantitative synthesis of single-subject research. Research in Developmental Disabilities. 24:2003;120-138
7. Hurley A.D. The misdiagnosis of hallucinations and delusions in persons with mental retardation: A neurodevelopmental perspective. Seminars in Clinical Neuropsychiatry. 1:1996;122-133
8. Kalachnik, J. E., Leventhal, B. L., James, D. H., Sovner, R., Kastner, T. A., Walsh, K., et al. (1998). Guidelines for the use of psychotropic medication. In S. Reiss, & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The international consensus handbook (pp. 45-72). Ohio: The Ohio State University Nisonger Center.
9. Martin J.E., Agran M. Psychotropic and anticonvulsant drug use by mentally retarded adults across community residential and vocational placements. Applied Research in Mental Retardation. 6:1985;33-49
10. Matson J.L., Bamburg J.W., Mayville E.A., Pinkston J., Bielecki J., Kuhn D., et al. Psychopharmacology and mental retardation: A ten-year review (1990-1999). Research in Developmental Disabilities. 21:2000;263-296
11. Matson J.L., Bielecki J., Mayville S.B., Matson M.L. Psychopharmacology research for individuals with mental retardation: Methodological issues and suggestions. Research in Developmental Disabilities. 24:2003;149-157
12. Molyneux P., Emerson E., Caine A. Prescription of psychotropic medication to people with intellectual disabilities in primary health-care settings. Journal of Applied Research in Intellectual Disabilities. 12:1999;46-57
13. Nøttestad J.Aa., Linaker O.M. Psychotropic drug use among people with intellectual disability before and after deinstitutionalization. Journal of Intellectual Disability Research. 47:2003;464-471
14. Pyles D.A.M., Muniz K., Cade A., Silva R. A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Research in Developmental Disabilities. 18:1997;185-214
15. Reiss S., Aman M.G. The international consensus process on psychopharmacology and intellectual disability. Journal of Intellectual Disability Research. 41:1997;448-455
16. Rinck, C. (1998). Epidemiology and psychoactive medication. In S. Reiss, & M. G. Aman (Eds.), Psychotropic medications and developmental disabilities: The international consensus handbook (pp. 31-44). Ohio: The Ohio State University Nisonger Center.
17. Schaal D.W., Hackenberg T. Toward a functional analysis of drug treatment for behavior problems of people with developmental disabilities. American Journal on Mental Retardation. 98:1994;123-140
18. Sevin J.A., Bowers-Stephens C., Hamilton M.L., Ford A. Integrating behavioral and pharmacological interventions in treating clients with psychiatric disorders and mental retardation. Research in Developmental Disabilities. 22:2001;463-485
19. Stone R.K., Alvarez W.F., Ellman G., Hom A.C., White J.F. Prevalence and prediction of psychotropic drug use in California developmental centers. American Journal on Mental Retardation. 93:1989;627-632
20. Sturmey P. Diagnostic-based pharmacological treatment of behavior disorders in persons with developmental disabilities: A review and a decision-making typology. Research in Developmental Disabilities. 16:1995;235-252
21. Sturmey, P. (1999). Classification: concepts, progress and future. In N. Bouras (Ed.), Psychiatric and behavioural disorders in persons with developmental disabilities and mental retardation (pp. 3-17). Cambridge: Cambridge University Press.